Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomography Imaging Study
Latest Information Update: 12 Feb 2026
At a glance
- Drugs Ziltivekimab (Primary)
- Indications Atherosclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ZEPHYR
- Sponsors Novo Nordisk
Most Recent Events
- 11 Dec 2025 Planned number of patients changed from 283 to 323.
- 11 Nov 2025 New trial record